GC Biopharma and Hanmi license Fabry disease drug to BioMarin for $475M

GC Biopharma and Hanmi Pharm signed an exclusive licensing deal with BioMarin for LA-GLA, a next-generation Fabry disease treatment candidate. The deal totals $475 million, including $70 million upfront and up to $405 million in milestones plus royalties. The drug is in global Phase 1/2 trials.

• Upfront payment is $70 million; total deal value reaches $475 million
• LA-GLA is a long-acting ERT designed as a self-administered subcutaneous injection
• The candidate received FDA orphan drug designation in 2024
• BioMarin handles global development and commercialization; partners lead in Korea